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Abstract
Background: As-needed formoterol can effectively relieve asthma symptoms. Since budesonide/formoterol is
available as maintenance and reliever therapy in Asia, formoterol is now being used as-needed, but always with
concomitant inhaled corticosteroids. The objective of this analysis was to assess the safety and efficacy of formoterol
therapy in patients in East Asia (China, Indonesia, Korea, the Philippines and Singapore) with asthma.
Methods: Post-hoc analyses of data from the East Asian population of the RELIEF (REal LIfe EFfectiveness of Oxis®
Turbuhaler® as-needed in asthmatic patients; study identification code: SD-037-0699) study were performed.
Results: This sub-group comprised 2834 randomised patients (formoterol n = 1418; salbutamol n = 1416) with mean
age 35 years; 50.7 % were male. 2678 patients completed the study. There was no significant difference in the total
number of adverse events (AEs) reported in the formoterol and salbutamol groups (21.3 % vs 20.9 % of patients;
p = 0.813), nor in the total number of serious AEs and/or discontinuations due to AEs (4.6 % vs 5.5 %, respectively;
p = 0.323). Compared with salbutamol, formoterol was associated with a significantly longer time to first
exacerbation (hazard ratio 0.86; p = 0.023) and a 14 % reduction in the risk of any exacerbation (p < 0.05).
Relative to salbutamol, mean adjusted reliever medication use throughout the study was significantly lower in
the formoterol group (p = 0.017) and the risk of increased asthma medication use was 20 % lower with
formoterol (p = 0.005).
Conclusions: Among patients with asthma in East Asia, as-needed formoterol and salbutamol had similar safety
profiles but, compared with salbutamol, formoterol reduced the risk of exacerbations, increased the time to first
exacerbation and reduced the need for reliever medication.
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Background
Current guidelines from the Global INitiative for
Asthma (GINA) recommend an inhaled short-acting
β2-agonist (SABA), such as salbutamol, terbutaline,
fenoterol, levalbuterol, reproterol or pirbuterol, for
the relief of symptomatic bronchoconstriction [1].
Formoterol is a long-acting β2-agonist (LABA) with a
rapid onset of action and is recommended by GINA
as an effective reliever medication in patients on
regular controller therapy with inhaled corticosteroids
(ICS) [1]. As-needed formoterol has previously been
assessed [2, 3] and has been shown to effectively
relieve asthma symptoms; a systematic review showed
that formoterol used as reliever therapy reduced the
number of exacerbations requiring oral corticosteroid
treatment [4].
To determine the comparative efficacy and safety of
formoterol and salbutamol as reliever therapy in patients
with asthma, the global RELIEF study (REal LIfe EFfect-
iveness of Oxis® Turbuhaler® as-needed in asthmatic pa-
tients) was conducted [5]. In this 6-month, international,
randomised, parallel-group study more than 18,000
* Correspondence: huangshaoguang@vip.163.com
1Department of Pulmonary Disease, Ruijin Hospital, Shanghai Jiao Tong
University, No.150 Wu Yi Road, Shanghai 200025, China
Full list of author information is available at the end of the article
© 2016 Cheng et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cheng et al. BMC Pulmonary Medicine  (2016) 16:8 
DOI 10.1186/s12890-015-0166-0
adults and children with asthma from 24 countries used
either formoterol or salbutamol as reliever therapy. The
study was designed to mimic real-world clinical practice
and therefore was open-label (i.e. no blinding), had min-
imal entry criteria and no run-in period; patient adher-
ence to treatment was not monitored, as treatment was
provided as-needed. The study included a large group of
patients of varying age and asthma severity and who
were receiving various maintenance medications. Over-
all, the safety profile of formoterol was similar to that of
salbutamol (i.e. no significant differences in adverse
events [AEs], serious AEs [SAEs] and discontinuations
due to AEs [DAEs]), but patients treated with formoterol
experienced a longer time to first exacerbation and re-
quired less as-needed and maintenance medication.
The availability of budesonide/formoterol as a main-
tenance and reliever therapy (Symbicort® SMART™) in
countries in the Asia-Pacific region, including China,
Japan, the Philippines and Thailand, means that formo-
terol in combination with ICS is now being used by
these patients as a reliever therapy. Therefore, it is im-
portant to understand the safety of formoterol in such
patients. Since limited real-world data exist regarding
the comparative safety and efficacy of formoterol and
salbutamol reliever medication in patients in East-Asia,
a post-hoc analysis was performed to examine safety and
efficacy outcomes among patients in the RELIEF study
recruited from East-Asian countries.
Methods
Study design
The methodology and primary results from the RELIEF
study (AstraZeneca study code: SD-037-0699) have been
reported previously [5]. Briefly, an international, rando-
mised, open-label, parallel-group, real-world study was
performed in 24 countries to examine the safety and ef-
fectiveness of formoterol or salbutamol as reliever medi-
cation for asthma; >18,000 patients with varying degrees
of asthma severity, background medication history and
aged ≥6 years were randomised to receive formoterol or
salbutamol as-needed for 6 months.
Patient population
This post-hoc analysis includes data from the ‘eastern re-
gion’ subgroup, which comprised only patients recruited
from China, Indonesia, Korea, the Philippines and
Singapore. All findings described herein are derived
from this population (unless otherwise stated) and writ-
ten informed consent was obtained from, or on behalf
of, all patients at the time the RELIEF study was con-
ducted. Approval for this study was obtained from all
relevant regulatory agencies. The study protocol was ap-
proved by the Independent Ethics Committee at the
leading site (Ruijin Hospital, Ministry of Health),
following approval by all local ethics committees at all
study centres (Additional file 1: Table S1).
Treatments
Patients were randomised to receive either formoterol
(Oxis® Turbuhaler®; AstraZeneca, Lund, Sweden; 4.5 μg per
delivered dose) or salbutamol (pressurised metered-dose
inhaler [pMDI]/dry powder inhaler [DPI]; Diskhaler®
[200 μg per dose; Ventolin™, GlaxoSmithKline, Uxbridge,
UK], Diskus® [200 μg per dose; Ventolin™, GlaxoSmithK-
line, Uxbridge, UK] or Turbuhaler® [100 μg per dose;
Inspiryl®, AstraZeneca, Lund, Sweden]), treatment was
available to patients on the first day of the study immedi-
ately after randomization. Since these therapies were pro-
vided on an as-needed basis, compliance was not
measured.
Assessments
Clinic visits occurred at study entry and after 1, 3 and
6 months of treatment. The study was divided into three
periods: Period 1 (study entry to end of first month),
Period 2 (second and third months) and Period 3 (re-
mainder of study).
The primary safety variables were asthma-related and
non-asthma-related AEs, SAEs and DAEs. SAEs were
defined as: any event causing hospitalization, prolonga-
tion of hospitalization, significant or persistent disability
or congenital abnormality, any life-threatening condition
or death. DAEs could be caused by serious or non-
serious AEs.
The following events were defined as exacerbations due
to deterioration of asthma: (1) any increase in mainten-
ance asthma medication; (2) ≥5 days of oral corticosteroid
treatment; (3) emergency treatment with corticosteroid in-
jection or nebulised β2-agonist; (4) hospitalization. Severe
exacerbations were defined as any one of events 2–4. Effi-
cacy variables included time to first exacerbation; numbers
of patients with exacerbations (all types); change in use of
study medication; days with asthma symptoms.
Statistical analyses
Statistical analyses were performed by intention-to-treat.
A logistic regression model with factor treatment was
applied within each stratum for the analysis of number
of patients with at least one AE/SAE/DAE/asthma ex-
acerbation. Results are expressed as odds ratios (ORs)
with 95 % confidence intervals (CIs). The time to first
asthma exacerbation was compared between treatments
using a Cox proportional hazards model with factors
treatment, stratum and interaction treatment by stratum.
Results are expressed as hazard ratios (HRs) with 95 %
CIs within each stratum, with the p-value for the inter-
action test. Time to first exacerbation (of any type) is pre-
sented in a Kaplan–Meier plot. Use of study medication
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and asthma symptom days were compared between treat-
ments using a linear mixed-effects model; within this
model adjustments were made for treatment, period and
interaction treatment by period, for each stratum separ-
ately. The limited number of patients in this subgroup
precluded analysis stratified by age or severity.
Results
Patients
The subgroup of patients recruited from East-Asian
countries comprised 2834 patients (n = 1418 in the for-
moterol group and n = 1416 in the salbutamol group);
2678 (94.5 %) patients completed the study (1352 and
1326, respectively). Reasons for not completing the study
included: not receiving treatment or no data on treat-
ment (n = 16 and n = 23 in the formoterol and salbuta-
mol treatment groups, respectively); discontinuation due
to AEs (n = 15 and n = 17), lost to follow-up (n = 19 and
n = 31), eligibility criteria not fulfilled (n = 0 and n = 1)
or other reasons (not specified; n = 16 and n = 18).
The majority of patients were of Oriental descent
(98.3 %). The mean age was 35 (range 5–85) years and
50.7 % were male. Patient baseline demographics/charac-
teristics were evenly distributed between the two groups
(Table 1). The demographics of this subgroup were simi-
lar to those of the entire study population [5] and to
patients in other regional subgroups (Additional file 1:
Table S2).
Prior to randomization, a similar proportion of pa-
tients in each treatment group were receiving treatment
for asthma. The majority of patients in each treatment
group were prescribed ICS (63.8 % of those in the for-
moterol group, mean dose 452 μg [range 40–1600 μg]
budesonide equivalents; 64.1 % in the salbutamol group,
mean dose 477 μg [range 40–1600 μg] budesonide
equivalents). LABAs were used by 5.4 % and 6.4 %, re-
spectively, while oral β2-agonists/xanthines were used by
43.2 % and 44.3 % of patients, respectively (at the time
this study was conducted, xanthines were considered to
be an effective and inexpensive treatment for asthma,
ideal for use in countries with more limited resources;
hence, the high level of baseline use reported here).
The use of muscarinic receptor antagonists as con-
comitant medication was permitted during the study;
however, there is no specific information on usage of
this medication type prior to randomization.
Safety
AEs
There was no significant difference in the percentage of
patients reporting AEs in the formoterol or salbutamol
groups (21.3 % vs 20.9 % of patients; OR 1.02, 95 % CI
0.85, 1.23; p = 0.81, Table 2). Total AEs included asthma-
related AEs, non-asthma-related AEs and cardiovascular-
related AEs.
SAEs and/or DAEs
There was no significant difference in the proportion of
patients reporting SAEs and/or DAEs between the two
groups (4.6 % of formoterol- vs 5.5 % of salbutamol-
treated patients; OR 0.84, 95 % CI 0.60, 1.18; p = 0.323,
Table 3). SAEs were reported by a similar proportion of
patients in the formoterol and salbutamol groups (3.8 %
vs 4.7 %, respectively), as were DAEs (1.1 % vs 1.2 %).
There were no significant differences between groups for
the proportion of asthma-related DAEs (0.6 % vs 0.3 %),
non-asthma-related DAEs (0.4 % vs 0.9 %), SAE-related




Compared with salbutamol, treatment with formoterol
was associated with a 14 % longer time to first exacerba-
tion (HR 0.86; 95 % CI 0.75, 0.98; p = 0.023, Fig. 1),
which also corresponds to a 14 % reduction in overall
exacerbation risk (p < 0.05, Fig. 2). The risk of severe ex-
acerbations was 18 % lower with formoterol than
Table 1 Demographic and baseline clinical characteristics
Characteristic Formoterol Salbutamol All
(n = 1418) (n = 1416) (n = 2834)
Male 736 (51.9) 700 (49.4) 1436 (50.7)
Mean age, years (range) 35 (5–81) 36 (6–85) 35 (5–85)
Age groups
Children ≤11 years 254 (17.9) 258 (18.2) 512 (18.1)
Adolescents 12–17 years 121 (8.5) 111 (7.8) 232 (8.2)
Adults 18–64 years 957 (67.5) 946 (66.8) 1903 (67.1)
Elderly ≥65 years 86 (6.1) 101 (7.1) 187 (6.6)
Race
Oriental 1397 (98.5) 1389 (98.1) 2786 (98.3)
Caucasian 4 (0.3) 8 (0.6) 12 (0.4)
Other 17 (1.2) 19 (1.3) 36 (1.3)
Asthma severity (judged by asthma medication level)*
Intermittent 206 (14.5) 201 (14.2) 407 (14.4)
Mild 740 (52.2) 713 (50.4) 1453 (51.3)
Moderate 299 (21.1) 318 (22.5) 617 (21.8)
Severe 173 (12.2) 184 (13.0) 357 (12.6)
Regular smoker 158 (11.1) 148 (10.5) 306 (10.8)
Data are presented as n (%) patients, unless otherwise stated
* Intermittent: no maintenance treatment; mild: inhaled corticosteroid (ICS)
<500 μg/day (<400 μg/day in children) or a regular long-acting β2-agonist
(LABA), cromone, theophylline or leukotriene modifier; moderate: ICS alone at
any dose ≥500 μg/day (≥400 μg/day in children), or ICS 500–800 μg/day
(400–800 μg/day in children) in combination with LABA, theophylline or
leukotriene modifier; severe: ICS >800 μg/day in combination with LABA,
theophylline, leukotriene modifier, or oral corticosteroids
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salbutamol (OR 0.82, 95 % CI 0.69, 0.99; p = 0.037.
Fig. 2). There was a significantly lower (−20 %) risk of
requirement of increased asthma medication on formo-
terol compared with salbutamol (HR 0.80; 95 % CI 0.69,
0.93; p < 0.005).
There was a non-significant difference in the proportion
of patients who experienced hospitalizations favouring for-
moterol (n = 33 [2.4 %] and 48 [3.4 %], respectively, p = 0.08
vs salbutamol). Emergency treatments (n = 133 [9.5 %] and
149 [11.4 %], p = 0.84) or oral corticosteroid treat-
ments (n = 123 [8.8 %] and 138 [9.9 %], p = 0.27) were
not different between treatments.
Use of formoterol or salbutamol
Over the course of the study, mean daily reliever medica-
tion use decreased in both treatment groups (Table 4) but
was significantly lower with formoterol compared with
salbutamol during all three study periods. The difference
was −0.20 (95 % CI −0.37, −0.04; p = 0.017) at the end of
Period 1 and −0.31 (95 % CI −0.48, −0.14; p < 0.001) at
the end of Period 2; the mean difference then remained
relatively stable until the end of Period 3 (−0.30; 95 % CI
−0.47, −0.13; p < 0.001, Table 4). Compared with salbuta-
mol, formoterol was associated with 20 % less study medi-
cation use. While patients in the formoterol group had
numerically fewer asthma symptom days than patients
using salbutamol, the difference between groups was not
significant (p ≥ 0.24, Table 4).
Discussion
The real-world global RELIEF study compared formo-
terol and salbutamol as reliever medication in a diverse
group of patients with varying degrees of asthma severity
and using a variety of maintenance treatments [5]. The
RELIEF study found that formoterol was at least as safe
as salbutamol when used as reliever medication, and that
finding was reproduced during this post-hoc analysis of
the East Asian patient subgroup. While the overall find-
ings for both analyses are similar, key differences were
noted between the full patient population and this sub-
group. In the full study, significantly fewer asthma-related
AEs and non-asthma-related AEs such as headaches,
tremor and allergic rhinitis were reported for formoterol
compared with salbutamol; however, there were also a
significantly greater number of total DAEs (caused by
non-serious AEs), asthma-related DAEs and non-asthma-
related DAEs (including tremor, headache and tachycar-
dia) reported for formoterol compared with salbutamol.
By contrast, the East Asian subgroup analysis found no
significant differences in risk of any AE (including SAEs
and DAEs) between formoterol and salbutamol reliever
treatments. There was a significant reduction in the risk of
any exacerbation (14 %) and severe exacerbations (18 %)
with use of formoterol compared with salbutamol. Formo-
terol treatment significantly increased the time to first ex-
acerbation and reduced the need for additional reliever
medication compared with salbutamol (−20 %).
The primary results of the global RELIEF study
showed that the proportion of patients with an AE was
similar between treatment groups (42 % of patients in
both formoterol and salbutamol groups experienced at
least one AE) as was the proportion of patients experi-
encing SAEs (3.1 % and 3.3 %, respectively). The most
commonly reported AEs included aggravated asthma
(12–13 % of each patient group) and nasopharyngitis
(5 %). The time to first exacerbation was longer with
formoterol (HR 0.86) and 16 % less as-needed medica-
tion was used in the formoterol group in the final treat-
ment period [5]. In this subgroup of patients in East
Asia, the results for SAEs (3.8 % and 4.7 %, respectively),
time to first exacerbation (HR 0.86) and as-needed
Table 2 Adverse event (AE) data and analysis
AEs Formoterol Salbutamol Odds ratio P
value(n = 1402) (n = 1393) (95 % CI)
Total AEs 298 (21.3) 291 (20.9) 1.02 (0.85, 1.23) 0.813
Asthma-related AE 56 (4.0) 69 (5.0) 0.80 (0.56, 1.15) 0.221
Non-asthma-related
AE
242 (17.3) 222 (15.9) 1.10 (0.90, 1.34) 0.347
Cardiovascular-
related AE
7 (0.5) 12 (0.9) 0.58 (0.23, 1.47) 0.250
Non-cardiovascular-
related AE
291 (20.8) 279 (20.0) 1.05 (0.87, 1.26) 0.633
Data are presented as n (%) patients
CI, confidence interval
Table 3 SAE/DAE data and analysis
Variable Formoterol Salbutamol Odds ratio P
value(n = 1402) (n = 1393) (95 % CI)
Total SAE and/or DAEs 65 (4.6) 76 (5.5) 0.84 (0.60, 1.18) 0.323
Serious adverse events 53 (3.8) 65 (4.7) 0.80 (0.55, 1.16) 0.245
Deaths 2 (0.1) 4 (0.3) 0.50 (0.09, 2.71) 0.419
Asthma-related SAE 41 (2.9) 51 (3.7) 0.79 (0.52, 1.20) 0.276
Non-asthma-related
SAE
12 (0.9) 14 (1.0) 0.85 (0.39, 1.85) 0.682
Cardiovascular-
related SAE
1 (0.1) 5 (0.4) 0.20 (0.02, 1.70) 0.140
Discontinuations due
to AE
15 (1.1) 17 (1.2) 0.88 (0.44, 1.76) 0.709
Asthma-related DAE 9 (0.6) 4 (0.3) 2.24 (0.69, 7.30) 0.180
Non-asthma-related
DAE
6 (0.4) 13 (0.9) 0.46 (0.17, 1.20) 0.113
SAE-related DAE 3 (0.2) 6 (0.4) 0.50 (0.12, 1.99) 0.322
Non-SAE-related
DAE
12 (0.9) 11 (0.8) 1.09 (0.48, 2.47) 0.846
Data are presented as n (%) patients
CI, confidence interval
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medication use (reliever use for formoterol was 18 %
lower than salbutamol in the final treatment period) all
favoured formoterol to a similar, if not the same, extent
as in the main study population. Interestingly, only
21 % of patients recruited from East-Asian countries re-
ported an AE compared with 42 % of the global RELIEF
study population. It is possible that this result reflects
cultural differences in study populations with regard to
reporting events.
It should also be noted that the East Asian patient
subgroup had high baseline levels of xanthine/oral β2-
agonist use (almost half of all patients); this information,
in conjunction with the low AE rate reported in this
subanalysis, suggests the relative safety of the addition of
formoterol to concomitant xanthine/oral β2-agonist and
maintenance therapy. This cannot be confirmed, how-
ever, as the analysis was not designed to investigate this
point, and the potential influence of cultural differences
(as stated above) should also be considered.
The results of the global RELIEF study and this sub-
group analysis of patients in East Asia are consistent
with those described in the literature, in which more
favourable efficacy outcomes with formoterol and similar
safety profiles have been reported (compared with salbu-
tamol) and no significant differences observed in sub-
groups from Asia [4, 6, 7]. A Cochrane review of
formoterol treatment in chronic asthma found that com-
pared with regular salbutamol or terbutaline, there was
no significant increase in fatal or non-fatal SAEs with
formoterol [6]. Another Cochrane review compared for-
moterol and SABAs when used as reliever medication in
adults and children with asthma [4]. This review
grouped all SABAs and found a significant effect in
favour of formoterol versus any SABA for an exacerba-
tion that was treated with oral corticosteroids. While
there were fewer SAEs in patients who received formo-
terol, this did not reach statistical significance versus
SABAs [4].
Recent data have shown that corticosteroid insensitivity
may be reversed by formoterol treatment. The actions of
formoterol and salbutamol were compared in an in vitro
study using peripheral blood mononuclear cells from
Fig. 1 Kaplan–Meier plot of time to first exacerbation
Fig. 2 Reduction in exacerbation risk with formoterol versus salbutamol (%)
Table 4 Analysis of study medication use and days with asthma
symptoms
Formoterol Salbutamol Mean difference P value
(n = 1402) (n = 1393) (95 % CI)
Use of study medication, doses/day (adjusted mean)
Period 1 1.62 1.83 −0.20 (−0.37,−0.04) 0.017
Period 2 1.52 1.83 −0.31 (−0.48,−0.14) < 0.001
Period 3 1.36 1.66 −0.30 (−0.47,−0.13) < 0.001
Asthma symptom days, % (adjusted mean)
Period 1 43.5 44.4 −0.92 (−3.92, 2.08) 0.55
Period 2 43.1 44.5 −1.41 (−4.42, 1.61) 0.36
Period 3 39.1 40.9 −1.83 (−4.86, 1.19) 0.24
CI, confidence interval
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patients with severe asthma or COPD [8]. Formoterol was
found to reverse corticosteroid insensitivity in both cell
types, while salbutamol was found to be effective only in
cells from patients with severe asthma. Although these
data are preliminary, this may be of interest when consid-
ering the suitability of formoterol treatment for patients
with severe asthma or asthma-COPD overlap syndrome.
The uniformity of results between the global RELIEF
population and the East Asia subgroup is consistent with
a sub-analysis of the COSMOS study, where the efficacy
and safety of budesonide/formoterol maintenance and
reliever therapy was compared with salmeterol/flutica-
sone propionate plus as-needed salbutamol [7]. Out-
comes observed in patients enrolled across East-Asian
countries (specifically China, Korea, Taiwan and Thailand)
were consistent with those in the overall study population
[5].
Strengths of the RELIEF study included minimal entry
criteria (with respect to age, comorbidities and concomi-
tant medications) as well as the absence of a run-in
period and lung function or compliance monitoring.
These features were deliberately chosen to maximise pa-
tient recruitment and ensure that the patient population
and procedures reflected everyday clinical practice. This
study also comprised a large patient population and was
of a sufficient duration to detect treatment effects. The
open-label nature of the study means that the data can
be generalised to the real-world population of patients
being treated in everyday clinical practice.
Limitations of the study design include the fact that
the primary inclusion criterion for this subgroup analysis
was based on residence and patients were not recruited
based on ethnic origin. However, a very small proportion
of patients in this analysis were not of Oriental descent,
and it is unlikely that the results were skewed by the in-
clusion of 48 patients who were of Caucasian or other
descent. As with any post-hoc analysis, the analysis is
limited to the data that were originally collected. Such
data could contain factors that are not apparent and
could influence the results (e.g. patient characteristics or
genetic factors that were not assessed).
The study investigators were permitted to adjust main-
tenance treatment as required according to clinical need,
and any increase in asthma medication was defined as
an exacerbation. Given the open-label nature of the
study design there was consequently the potential for
bias, as investigators had the option to increase asthma
medication and consequently increase the apparent ex-
acerbation rate.
The lack of information on patient adherence to treat-
ment is another limitation of this study. Since treatment
was provided as required, it would be difficult to distin-
guish between non-adherent patients (e.g. patients ex-
periencing symptoms, but not using their medication or
with few symptoms but over-using their medication) and
adherent patients (e.g. those with fewer symptoms who
have a reduced need for as-needed treatment or vice
versa). Therefore, adherence monitoring was not
attempted. However, as stated previously, the advantages
of an open-label study (wide applicability to real-world
practice) were thought to outweigh these potential
limitations.
It is now widely acknowledged that when used alone,
LABAs are associated with risks of increased exacerba-
tions and increased mortality in patients with asthma
compared with ICS/LABA [9, 10]. However, the addition
of a LABA to an ICS is beneficial and the risk of death,
intubation or hospital admissions for exacerbations is
not increased with combination LABA and ICS therapy
versus ICS alone [11]. All guidelines stress that LABAs
should not be used without concomitant ICS treatment
[9–11]. In the time since the main RELIEF study was
conducted, the treatment landscape has changed and
LABA-only regimens are not recommended in patients
with asthma. Hence further studies using only formoterol
or salbutamol will not be conducted. However, similar
post-hoc analyses may help to elucidate whether or not
differences exist between other regional or ethnic sub-
groups and broad, mixed populations.
Conclusion
This post-hoc analysis of the global RELIEF study dem-
onstrates that among patients with asthma in East Asia,
as-needed formoterol and salbutamol had similar safety
profiles but formoterol reduced the risk of exacerba-
tions, increased the time to first exacerbation and re-
duced the need for reliever medication compared with
salbutamol.
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Abbreviation
AE: Adverse event; CI: Confidence interval; DAE: Discontinuation due to
adverse event; DPI: Dry powder inhaler; GINA: Global INitiative for Asthma;
HR: Hazard ratio; ICS: Inhaled corticosteroid; LABA: Long-acting β2-agonist;
OR: Odds ratio; RELIEF: REal Life EFfectiveness of Oxis® Turbuhaler® as-needed
in asthmatic patients; SABA: Short-acting β2-agonist; SAE: Serious adverse
event.
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